SOPHiA DDM -For Liquid Biopsy
Pioneering Innovation, Streamlining Adoption: We are pushing the boundaries of today’s liquid biopsy capabilities. Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to comprehensive report in record time. Powered by state-of-the-art proprietary algorithms, the SOPHiA DDMTM Platform reveals deep genomic insights from cell-free DNA, advancing your oncology research to new horizons.
Do you need a tailor-made solution to overcome your laboratory’s unique challenges? Get ready to embrace liquid biopsy.
Consult with our brilliant team of experts and embark on your liquid biopsy journey with:
- An in-house wet lab workflow seamlessly integrated with the cloud-based analytics of the SOPHiA DDM™ Platform.
- Customizable gene content, focusing exclusively on the most vital biomarkers for your lab.
- Accurate detection of biologically actionable variants and biomarkers, including SNVs, Indels, fusions, and CNVs.
But that’s not all – if you’re already using SOPHiA DDM™ applications for solid tumor and homologous recombination repair (HRR) gene analysis, we’ve got you covered. You can add CUMIN™ technology to your workflow, maximizing the power of your current set-up.
CUMIN is a proprietary unique molecular identifier (UMI) technology, designed to transform the way you analyze cell-free DNA samples with3,4:
- Sensitive detection: detect variants with precision even at low frequency (down to 0.5% VAF), leveraging an alternative encoding approach.
- Minimal input DNA: start from just 25 ng cell-free DNA.
- Exceptional performance: experience comparable analytical performance to traditional UMIs.
- Noise suppression: efficiently eliminate background noise for results you can trust.
- Reliable quantification: obtain accurate molecule-based allele frequencies.
MSK-ACCESS® is a comprehensive liquid biopsy test developed by Memorial Sloan Kettering Cancer Center (MSK) that covers non-invasive cancer genomic profiling and disease monitoring1,2. It involves the deep sequencing of 146 key cancer-associated genes selected from MSK’s solid tumor genomic-profiling assay, MSK-IMPACT®.
Interested in adopting an in-house version of MSK-ACCESS®, enhanced with the advanced analytics of the SOPHiA DDM™ Platform?
SOPHiA GENETICS is collaborating with MSK to decentralize MSK-ACCESS® for liquid biopsy. By combining MSK’s clinical expertise in cancer genomics, the predictive algorithms of the SOPHiA DDMTM Platform, and the power of the global SOPHiA GENETICS community, the collaboration aims to expand access to precision cancer analysis capabilities worldwide.
